摘要
目的:探讨尼洛替尼在伊马替尼耐药的慢性髓系白血病(CML)患者中的疗效及不良反应。方法:9例伊马替尼耐药的CML患者,其中慢性期6例,进展期3例,持续口服尼洛替尼400mg 2次/d,观察其疗效及不良反应。结果:6例CML慢性期患者,5例获得完全血液学反应,2例获得主要细胞遗传学反应;3例CML进展期患者均获得血液学缓解。平均用药时间为18.2个月,其中2例进展期患者因用药仅1个月,尚未进行相关细胞遗传学及分子生物学检测评估疗效。9例患者中8例耐受良好,不良反应多不严重,经对症处理后缓解,仅1例因心脏不良反应停止用药。结论:尼洛替尼对于伊马替尼耐药的CML患者是有效的,且耐受性良好。
Objective：To observe the efficacy and adverse effects of nilotinib in the treatment of patients with chronic myeloid leukemia（CML） after imatinib resistance.Method：Nine patients with CML after imatinib resistance,in Department of Hematology,Union Hospital affiliated to Tongji Medical College,Huazhong University of Science and Technology,received oral nilotinib at dose of 400mg twice daily.Of them,6 patients were in chronic phase and 3 patients were in advanced phase（blastic phase or accelerated phase）.Result：In 6 patients with CML in chronic phase,5 patients achieved CHR,2 patients achieved MCyR.Three patients with CML in advanced phase all achieved hematological remission.The average treatment duration was 18.2 months.As 2 patients with CML in advanced phase had only been treated for 1 months,we did not carry out the detection of cytogenetics and molecular biology to evaluate the efficacy.Eight patients had a good tolerance to nilotinib.The adverse effects were predominantly mild to moderate,and were generally controlled with appropriate supportive care.Only 1 patient discontinued treatment as a result of cardiac adverse effect.Conclusion：Nilotinib was effective in the treatment of patients with CML after imatinib resistance,and patients had good tolerance to nilotinib.
出处
《临床血液学杂志》
CAS
2011年第6期672-675,共4页
Journal of Clinical Hematology
